Miller Investment Management LP lowered its position in shares of VanEck Biotech ETF (NASDAQ:BBH – Free Report) by 51.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 38,925 shares of the company’s stock after selling 41,833 shares during the quarter. VanEck Biotech ETF comprises about 0.7% of Miller Investment Management LP’s portfolio, making the stock its 24th largest position. Miller Investment Management LP owned about 1.96% of VanEck Biotech ETF worth $7,367,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in the company. Flagship Harbor Advisors LLC acquired a new position in shares of VanEck Biotech ETF in the fourth quarter valued at about $47,000. Allworth Financial LP lifted its holdings in shares of VanEck Biotech ETF by 255.0% during the fourth quarter. Allworth Financial LP now owns 426 shares of the company’s stock worth $81,000 after purchasing an additional 306 shares during the period. Huntington National Bank purchased a new stake in VanEck Biotech ETF in the fourth quarter valued at approximately $132,000. Cibc World Market Inc. purchased a new stake in VanEck Biotech ETF in the third quarter valued at approximately $204,000. Finally, Focus Financial Network Inc. acquired a new position in VanEck Biotech ETF in the 4th quarter worth approximately $206,000. Hedge funds and other institutional investors own 32.05% of the company’s stock.
VanEck Biotech ETF Price Performance
BBH opened at $183.08 on Thursday. VanEck Biotech ETF has a 12-month low of $150.18 and a 12-month high of $202.91. The firm has a 50 day moving average of $186.95 and a two-hundred day moving average of $190.68.
VanEck Biotech ETF Profile
The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.
Featured Articles
- Five stocks we like better than VanEck Biotech ETF
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
